Should Clinicians Recommend Genetic Testing to Family Members of Patients with Breast Cancer History?
For clinicians who care for patients with breast cancer, the possibility of a cancer diagnosis being related to a hereditary predisposition is always a consideration. The potential benefit for identifying a hereditary breast cancer extends beyond the patient to other family members
and the risk may not be only for the development of breast cancers, but for other cancers as well. Once a mutation is identified in the patient, each first-degree relative has a 50% risk of carrying the mutation and ideally, it’s crucial that these family members consider genetic testing.
According to a study 1 performed on over 1000 Indian population with breast and ovarian cancer detected mutations in 304 cases (30.1%) with the majority of the mutations were detected in BRCA 1 and BRCA 2 genes (84.9%) compared with non-BRCA genes (15.1%). The study also reported that the high rate of detection of hereditary variants (75%) was observed in patients whose age at diagnosis was below 40 years and had a first degree family member affected by breast or ovarian cancer.
A 2018 lancet study reported that India continues to have a low survival rate for breast cancer – 66 percent 2. And a 2018 Globocan study reported the death rate due to breast cancer in India at 87,090 3. With alarming rates of breast cancer incidence and death rate, the need of the hour is early detection and diagnosis.
GENETIC TESTING – A SOLUTION FOR CHANGE
- Limited awareness by the public, complexity of the current structure, restricted genetic counseling services, and current testing pathways have facilitated restricted access and massive under use of genetic testing services 4,6.
- In fact, the use and importance of genetic testing is growing in the breast cancer space, especially as more targeted and personalized therapies are moving through the pipeline and into the clinic.
- Genetic testing for cancer genes with expanded panels can cover around 100 genes. It can identify other organs that may be at risk for cancer, such as pancreatic cancer or melanoma. It can also pinpoint others in a family who may harbor mutations.
- A major advantage of genetic testing is enabling testing in the relatives of breast cancer mutation carriers, to identify unaffected relatives carrying mutations who can benefit from early diagnosis and cancer prevention.
GENETIC COUNSELLING – ITS ROLE OF IMPORTANCE
The growing complexity of genetic testing options, including testing for panels of genes for which less information is available, make pre-test and post-test counselling important components of the process. Genetic counsellors are healthcare providers who are trained in genetics and the psychological effects of learning about inherited risk. Their skills include assessing the patient’s and their family history very thoroughly. They make an estimate of which genes are relevant to test by drawing a family tree, a pedigree, with all the cancers and other diseases in the family. They will explain to the patient the pros and cons of genetic testing and its current limitations.
Genetic counsellors also help patient’s to inform their family members and reach out to relatives, and guide them through appropriate testing. Genetic counsellors not only offer support and guidance to patients and families, but also become a bridge between the patient and the doctor. At truGeny, our certified genetic counsellors will help translate genetic information into clinical practice while navigating the psychological, ethical and legal pitfalls. To ensure access to quality genetic services for all individuals, truGeny offers genetic counselling services via tele-genetic sessions with a vision to improve patient’s access to health care in areas with geographical barriers, reducing the cost burden and saving time.
- Singh, J., Thota, N., Singh, S., Padhi, S., Mohan, P., Deshwal, S. & Ahmed, R. (2018). Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations.
Breast cancer research and treatment, 170(1), 189-196.
- Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., … & Ogunbiyi, O. J. (2018). Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients
diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. The Lancet, 391(10125), 1023-1075.
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 68(6), 394-424.
- Childers CP, Childers KK, Maggard Gibbons M, Macinko J. National estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol. 2017;35(34):3800-3806. doi:10.1200/ JCO.2017.73.6314
- Manchanda R, Blyuss O, Gaba F, et al. Current detection rates and time to detection of all identifiable BRCA carriers in the Greater London population.J Med Genet. 2018;55(8):538-545. doi:10.1136/jmedgenet-2017-105195
- Hughes KS. Genetic testing: what problem are we trying to solve? J Clin Oncol. 2017;35(34):3789- 3791. doi:10.1200/JCO.2017.74.7899
- Sun, L., Brentnall, A., Patel, S., Buist, D. S., Bowles, E. J., Evans, D. G. R. & Duffy, S. (2019). A Cost-effectiveness Analysis of Multigene Testing for All Patients with Breast Cancer. JAMA oncology.